Number of pages: 100 | Report Format: PDF | Published date: May 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
Report Attribute |
Details |
CAGR |
4.95% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Drug Class, Route of Administration, Distribution Channel, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global pyomyositis market is expected to register a revenue CAGR of 4.95% during the forecast period from 2023 to 2031.
Pyomyositis Market Fundamentals
Pyomyositis is a bacterial infection of the skeletal muscle tissue. Various bacterial strains, including Staphylococcus aureus, Streptococcus pyogenes, and Escherichia coli, cause it. The infection can occur in any skeletal muscle but is primarily found in the large muscles of the thigh and pelvis. Pyomyositis typically begins with localized muscle pain, tenderness, and swelling. The affected area may feel warm to the touch, and there may be redness or discoloration of the skin overlying the muscle. Patients may experience fever, chills, and fatigue as the infection progresses. Pyomyositis is more common in people with weakened immune systems or chronic diseases like diabetes or HIV/AIDS. It can also occur in healthy individuals, particularly those who have recently experienced trauma or surgery in the affected area. Treatment usually involves a combination of antibiotics and drainage of any abscesses that may have formed. In severe cases, surgery may be necessary to remove infected tissue.
The research study on the pyomyositis market overview thoroughly analyzes the market, along with the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth pyomyositis market forecast to the industry stakeholders.
Pyomyositis Market Dynamics
The rising prevalence of bacterial infections in the population is one of the primary drivers of the global pyomyositis market. The increasing incidence of pyomyositis in people with weakened immune systems or chronic diseases has created a significant demand for effective treatment options. For instance, according to the National Centre for Biotechnology Information’s article of December 2022, polymyositis and dermatomyositis have a prevalence rate of 5-22 per 100,000 people and an incidence rate of 1.2-19 per million people at risk each year. Moreover, the growing awareness of pyomyositis among healthcare professionals and the general population has increased diagnosis rates. The availability of advanced diagnostic technologies and better access to healthcare facilities has also contributed to the market's growth. Furthermore, the development of novel and effective treatment options, such as antibiotics and surgery, has boosted the growth of the pyomyositis market. The introduction of new antibiotics and therapies that target specific bacterial strains has enhanced the efficacy of treatment.
Additionally, limited awareness in low-income countries and high treatment costs impede the overall pyomyositis market growth.
Pyomyositis Market Ecosystem
Pyomyositis Market, by Drug Class
Pyomyositis Market, by Route of Administration
Pyomyositis Market, by Distribution Channel
Pyomyositis Market by Drug Class
[575675]
The antibiotic drug class segment accounted for a significant market revenue share. The choice of antibiotic therapy depends on the specific bacterial strain responsible for the infection, as well as the patient's overall health status and any underlying medical conditions. In general, antibiotics used to treat pyomyositis are broad-spectrum, meaning they are effective against a wide range of bacterial strains. Commonly used antibiotics include penicillins, cephalosporins, and fluoroquinolones. In cases where the bacterial strain is known to resist these antibiotics, other options may include vancomycin, clindamycin, or linezolid. The rising incidence of bacterial infection will also benefit the antibiotic drug class. For instance, according to the ReAct’s factsheet of December 2022, in 2019, 7.7 million deaths occurred due to bacterial infections, which is 1 in 8 of all global deaths.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as drug class, route of administration, and distribution channel. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential pyomyositis market growth opportunities.
Pyomyositis Market by Region
North America dominated the global pyomyositis market with the maximum revenue share, owing to the presence of key market players, favorable reimbursement policies, and fast adoption of technology. Additionally, there is ongoing research to develop more effective treatments for pyomyositis, including the use of novel antimicrobial agents and immunomodulatory therapies. In North America, these efforts are primarily driven by academic institutions and government organizations, with the support of pharmaceutical companies and other stakeholders in the healthcare industry.
Based on the regions, the global pyomyositis market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding pyomyositis market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
Pyomyositis Market Competitive Landscape
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the pyomyositis market industry trends.
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Pyomyositis is a bacterial infection of the skeletal muscle tissue. Various bacterial strains, including Staphylococcus aureus, Streptococcus pyogenes, and Escherichia coli cause it.
North American region will have the largest pyomyositis market size during the forecast period from 2023 to 2031.
The revenue CAGR of the pyomyositis market during the forecast period will be 4.95% from 2023 to 2031.
Increasing awareness and diagnosis is the most prominent pyomyositis industry trend.
The limited awareness in low-income countries and high treatment costs are key challenges hampering the growth of the global pyomyositis market.
Advancements in treatment options and the growing prevalence of bacterial infections are growth opportunities in the global pyomyositis market.
Some of the prominent players in the pyomyositis market are GlaxoSmithKline plc., Lupin Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Sanofi S.A, and AstraZeneca plc.
The antibiotic drug class segment has the highest share in the global pyomyositis market.
*Insights on financial performance are subject to the availability of information in the public domain